Companies › TaiMed Biologics
2 active drug programs in 2 registered trials: 2 Phase 2; Infectious disease; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TMB-365 HIV post-attachment inhibitor; monoclonal antibody that binds to CD4 receptor | CD4 | Phase 2 | HIV -1 Infection | May 2027 |
| TMB-380 Broadly neutralizing antibody (bNAb) against HIV; monoclonal antibody that binds to HIV en | ENV | Phase 2 | HIV -1 Infection | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07215468 | TMB-365 | Phase 2 | HIV -1 Infection | Infectious disease | May 2027 |
| NCT07215468 | TMB-380 | Phase 2 | HIV -1 Infection | Infectious disease | May 2027 |
Suzhou HepaThera Biotech Amplexd Therapeutics Sano Chemicals Hyundai Bioscience KTH Biopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.